Questcor Adds Angus C. Russell to Board of Directors

             Questcor Adds Angus C. Russell to Board of Directors

PR Newswire

ANAHEIM, Calif., June 10, 2013

ANAHEIM, Calif., June 10, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) today announced the addition ofAngus C. Russell,
recently-retired Chief Executive Officer of Shire plc, to Questcor's Board of

Shire is a global specialty biopharmaceutical company whose 2012 revenues
exceeded $4.6 billion. During Mr. Russell's five-year tenure as Chief
Executive Officer, Shire introduced several new products, grew revenues over
50%, and increased earnings approximately five-fold to $745 million.
Previously, Mr. Russell was Chief Financial Officer at Shire from 1999 to
2008, during which time its revenues grew from less than $220 million to
nearly $3 billion and its earnings grew from $20 million to $156 million.
Shire's market capitalization grew from $1.4 billion when Mr. Russell joined
the company in 1999 to $17.5 billion when he retired at the end of April.

"Angusis a respected biopharmaceutical industry leader with a proven track
record in specialty pharmaceuticals," said Virgil D. Thompson, Chairman of
Questcor's Board of Directors. "Over his many years at Shire, Angus
spearheaded and achieved numerous initiatives and helped to transform the
company into the global industry leader that it is today. We look forward to
benefitting from Angus' 32 years of experience in the specialty pharmaceutical
industry as we continue to focus on the treatment of patients serious,
difficult-to-treat autoimmune and inflammatory disorders." 

In addition to serving as Chief Executive Officer at Shire from 2008 until his
retirement in April 2013, Mr. Russellwas also the Chairman of Shire's
Leadership Team and was previouslya lead member of the Shire Management
Committee that devised and implemented Shire's long-term, focused business

"Questcor has succeeded in helping many patients with difficult-to-treat
autoimmune and inflammatory disorders over the last several years as the
Company has supported the rapid adoption of its unique product, H.P. Acthar^®
Gel by physicians in several medical specialties," Mr. Russell said. "The
growth of scientific knowledge regarding the importance of the melanocortin
receptors in immunomodulation provides Questcor with a large potential growth
opportunity over the next few years. I am pleased to join the Board at this
exciting time and look forward to helping the Company to pursue the many
opportunities that lie ahead."

Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for
19 years, most recently as Vice President of Corporate Finance at AstraZeneca
PLC. In that role he was responsible for financial input into merger and
acquisition activities, management of tax, legal and finance structure,
investor relations, and the management of various financial risks. Mr.
Russell also held a number of positions within Zeneca Group PLC from 1993
until 1999, including Group Treasurer. He is a chartered accountant, having
qualified with Coopers & Lybrand (now PricewaterhouseCoopers LLP).

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor also provides specialty contract
manufacturing services to the global pharmaceutical industry through its
wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P.
Acthar^® Gel (repository corticotropin injection), an injectable drug that is
approved by the FDA for the treatment of 19 indications. Of these 19
indications, Questcor currently generates substantially all of its net sales
from the following on-label indications: the treatment of proteinuria in the
nephrotic syndrome of the idiopathic type, or NS, the treatment of acute
exacerbations of multiple sclerosis, or MS, in adults, the treatment of
infantile spasms, or IS, in infants and children under two years of age, and
the treatment of certain rheumatology related conditions, including the
treatment of the rare and closely related neuromuscular disorders
dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA
has approved Acthar to "induce a diuresis or a remission of proteinuria in the
nephrotic syndrome without uremia of the idiopathic type or that due to lupus
erythematosus." Questcor is also exploring the possibility of developing
markets for other on-label indications and the possibility of pursuing FDA
approval of additional indications not currently on the Acthar label where
there is high unmet medical need. For more information about Questcor, please

For more information, please visit or

Note: Except for the historical information contained herein, this press
release contains forward-looking statements that have been made pursuant to
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future financial performance. In some cases, you can
identify forward-looking statements by terminology such as "ahead,"
"believes," "continue," "could," "ensuring," "estimates," "expects," "growth,"
"may," "momentum," "plans," "potential," "remain," "should," "start,"
"substantial," "sustainable" or "will" or the negative of such terms and other
comparable terminology. These statements are only predictions. Actual events
or results may differ materially. Factors that could cause or contribute to
such differences include, but are not limited to, the following:

  oOur reliance on Acthar for substantially all of our net sales and profits;
  oOur ability to continue to generate revenue from sales of Acthar to treat
    on-label indications associated with NS, MS, IS or rheumatology-related
    conditions, and our ability to develop other therapeutic uses for Acthar;
  oOur ability to effectively manage our growth, including the expansion of
    our sales forces, and our reliance on key personnel; and
  oOther risks discussed in Questcor's annual report on Form 10-K for the
    year ended December 31, 2012 as filed with the Securities and Exchange
    Commission, or SEC, on February 27, 2013, and other documents filed with
    the SEC.

The risk factors and other information contained in these documents should be
considered in evaluating Questcor's prospects and future financial

Questcor undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements, which may be made to reflect
events or circumstances after the date of this release.

For more information, please visit or

SOURCE Questcor Pharmaceuticals, Inc.

Contact: EVC Group, Gregory Gin/Patty Eisenhaur, +1-646-445-4801/
+1-951-316-0577, or Doug Sherk, +1-415-652-9100, Janine McCargo,
Press spacebar to pause and continue. Press esc to stop.